Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153690 (bone metastases)
 6,382 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The records of 158 patients irradiated for bone metastases were reviewed to evaluate the effectiveness of pain relief and to judge the effect of treatment on overall quality of life. Within 3 months 73% of the sites treated had pain relief, with 55%-65% having sustained relief up to 1 year or death. Of patients surviving more than 3 months, 63% maintained a satisfactory quality of life and were able to take care of most personal needs. The median survival of all patients was 1 year from initial treatment for bone metastasis. Radiation dose and the primary tumor site do not seem to be significant prognostic factors for initial pain relief or quality of life.
 ...
PMID:Evaluation of radiation therapy for bone metastases: pain relief and quality of life. 7 4

Radiotherapy of bone metastases can achieve in up to 78% of patients complete relief of pain. Recalcification avoids pathological fractures and beginning compression of the spinal cord. Depending on size and site of the osteolytic process a prophylactic surgical stabilisation will be necessary. Bone metastases are a sign of generalized disease. Systemic therapy should be provided in addition to local therapy.
 ...
PMID:[Management of bone metastases. Indication for radiotherapy and surgical internal fixation (author's transl)]. 8 16

42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis. Treatment was stopped in 2 patients before response could be assessed; of the other 40, 15 (37.5%) had an objective response, 1 (2.5%) showed a response in bone but not in soft tissue, and 4 (10%) had complete or very great relief of metastatic bone pain but no radiological evidence of improvement. 19 (53%) of 36 patients with bone metastases responded to treatment (15 had X-ray evidence and 4 had pain relief), as did 5 (45%) of 11 patients with soft tissue metastases, 2 (25%) of 8 with malignant marrow infiltration, 1 (14%) of 7 with lung metastases, and none of 13 with liver metastases. Response was commonest in patients who had previously responded to other forms of endocrine therapy. Side-effects, usually mild and transient, occurred in a few patients; the most important were an initial period of somnolence in 9 patients and a rash in 5.
 ...
PMID:Aminoglutethimide in treatment of metastatic breast carcinoma. 8 May 76

Pain relief from bone metastases is achieved in 80 percent of patients by local irradiation. Response to local irradiation is much faster in metastases from breast and lung than in prostate bone metastases. Local irradiation is also very effective in preventing pathological fractures in lytic bone lesions, and healing of the pathological fractures by new bone formation.
 ...
PMID:The role of radiotherapy in management of metastatic bone disease. 8 66

Fifteen patients with widespread painful osseous metastases from breast cancer unresponsive to other systemic therapy were treated with mithramycin at dose levels usually used for treating Paget's disease. Ten patients had relief of pain, which was marked and rapid in onset in seven. Mobility was greatly improved in four patients. Healing of bone lesions did not occur and new lesions developed while treatment was being given. Clinical response was associated with a decrease in plasma alkaline phosphatase. Toxicity was mild and consisted of nausea in most patients and a slight decrease in platelet count in one patient. Mithramycin is a useful agent for palliation of painful bone metastases and should be considered for further trials of combination chemotherapy for advanced breast cancer with bone metastases.
 ...
PMID:Effect of mithramycin on widespread painful bone metastases in cancer of the breast. 9 11

The efficacy of an association of cyclophosphamide (CPM) and 5-fluorouracil was studied in 15 patients with prostate cancer not responding to oestrogen therapy, and more particularly its effect on pain due to bone metastases. No objective improvement was noted with this association, but there was a definitite reduction in bone metastases pain in 5 of the patients, with an average remission time of 4 months. Half of the patients had nausea and vomiting, but in spite of this digestive intolerance those patients who obtained pain relief for 4 months considered the treatment to be of positive value. This therapy is recommended only fater the failure of castration, anti-androgens, and oestrogens, together with nitrogen mustard (Estracyt) and corticotherapy.
 ...
PMID:[Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)]. 9 8

The intravenous application of 89-strontium for the relief of pain in 43 patients with breast cancer, bronchogenic cancer, carcinoma of the prostate, hypernephroma and lymphoma with generalized bone metastases is reported. A remarkable clinical improvement was achieved in 33 (76.7%) patients. In four patients a transient analgesic effect was observed. In six cases no response could be achieved. The therapeutic effect usually was long-lasting. At the same time, an increase of alkaline phosphatase was observed, which was interpreted as an indication for the stimulation of osteoblasts and osteoid peripheral zones owing to beta-emission of the radioisotope in the affected areas. There was a significant correlation between the concentration of 85Sr in the bone scan and the therapeutic result of 89Sr-therapy. The indication for such therapy and possible late adverse effects of bone-seeking isotopes are discussed.
 ...
PMID:[Endo-osseous isotope therapy of malignant skeletal disease (author's transl)]. 14 38

A retrospective study of 36 cases of bone marrow metastases from carcinoma is reported. In all cases, the presence of tumour cells was confirmed by needle biopsy of the bone marrow. The clinical picture was fairly typical: decline in general health, fever, bony pain and skin and mucosal hemorrhages. Radiological lesions of the skeleton were present in 64% of cases. Sometimes the blood disorders were isolated. Anemia was almost constant (86), normochromic, normocytic, and may be associated with leukocytosis and thrombopenia. Pancytopenia is rarer as also is a rise in the number of platelets. Erythremia, very suggestive, is demonstrated in 73% of the blood smears. In 31% of the slides examined again, schizocytes were found among the normal red cells. Disorders of hemostasis were easily circumscribed. As fibrinolysis was sometime found, hemostasis was studied as a routine in all patients. The special recruitment of a hematology unit explains the high frequency of blood abnormalities in this series of bone metastases.
 ...
PMID:[Hematological and clinical manifestations of bone marrow metastasis of carcinomas. Apropos of 36 cases verified by biopsy]. 19 98

One hundred ninety patients with breast cancer were prospectively evaluated for bone pain and had technetium Tc 99m-methylene diphosphonate bone scintigraphy for bone metastases. Of the 66 patients showing evidence for bone metastases, 21 (32%) did not have bone pain. There were 155 sites of skeletal metastases, but pain was found only in 50 sites. The age of the patient or involvement of weight-bearing bones did not seem to affect the association between bone metastases and pain. We discuss the need for periodic bone scintigraphy, even when the clinical state does not seem to warrant it.
 ...
PMID:Bone metastases and bone pain in breast cancer. Are they closely associated? 48 Jun

The authors studied 75 patients with 158 areas of bone metastases from breast cancer treated by radiation therapy. The treatment regimen used was usually 2000 to 2500 rads delivered over a period of 2 weeks. Both subjective and objective responses were evaluated. This dose schedule proved to be highly effective in symptomatic relief and in healing osteolytic lesions; various levels of pain relief for about one year were observed in 96% (151/158 treatment areas), and radiographic evidence of recalcification was observed in 78% (73/94 treatment areas examined by serial radiography). After cases from previous studies were incorporated, the subjective response rate of the overall group was 91% (191/212) for a mean duration of 12 months, and the objective response rate was 75% (151/202) for a mean duration of 9 months.
 ...
PMID:The effectiveness of radiation therapy in the treatment of bone metastases from breast cancer. 61 16


1 2 3 4 5 6 7 8 9 10 Next >>